6 Minutes
by Michael Woodhead
August 20, 2010
Immunisation experts say there is no immediate need to consider switching from the current quadrivalent HPV vaccine (Gardasil) to a ‘stronger’ bivalent vaccine (Cervarix).
Major drug stores ramp up flu vaccine availability
Vaccine News Daily
by Ashton Daigle on August 19, 2010
While seasonal flu shots are already available in many local pharmacies across the country, retail pharmacy chains have begun changing their marketing plans to include new recommendations by the U.S. Centers for Disease Control.
Government to overhaul bioterror and pandemic flu plans
Federal officials will use H1N1 funding to speed the process of discovering and developing drugs and vaccines in case of emergency.
Los Angeles Times
By Andrew Zajac, Tribune Washington Bureau
August 20, 2010
Reporting from Washington —
Acknowledging that the development of medical countermeasures against bioterrorism threats and pandemic flu is lagging, federal authorities Thursday announced a $1.9-billion makeover of the system for identifying and manufacturing drugs and vaccines for public health emergencies.
Vaccine Hoax Uses Cancer Scare Tactics
OpEdNews
By K.L. Carlson
August 18, 2010
According to FDA documents, HPV infections do not lead to cervical cancer. “Most infections by HPV are short-lived and not associated with cervical cancer,” states an FDA news release dated March 31, 2003. According to another FDA document, the Gardasil vaccine has been found to increase the risk of developing precancerous lesions by more than 44 percent in young women already infected with the HP virus strains used in the vaccine.
Proof-of-Principle: Efficacy of fewer than 3-doses of a bivalent HPV 16/18 vaccine against incident persistent HPV infection in Guanacaste, Costa Rica
HPV 2010 Conference
Montreal Canada
July 3-8, 2010
Conclusion: Our data do not provide sufficient evidence to modify existing 3-dose schedules, but suggest that fewer than three doses may provide a high degree of protection against HPV-16/18 infection. Systematic evaluation of one- and two-dose schedules is justified.
